Fjarde Ap-fonden’s Idexx Laboratories IDXX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $20.3M | Sell |
38,532
-2,880
| -7% | -$1.62M | 0.1% | 195 |
|
|
2026
Q1 | $23.3M | Buy |
41,412
+17,440
| +73% | +$11.2M | 0.13% | 155 |
|
|
2025
Q4 | $16.2M | Buy |
23,972
+380
| +2% | +$259K | 0.14% | 143 |
|
|
2025
Q3 | $15.1M | Sell |
23,592
-1,900
| -7% | -$1.15M | 0.13% | 163 |
|
|
2025
Q2 | $13.7M | Buy |
25,492
+3,700
| +17% | +$1.77M | 0.13% | 168 |
|
|
2025
Q1 | $9.15M | Buy |
21,792
+800
| +4% | +$347K | 0.11% | 184 |
|
|
2024
Q4 | $8.68M | Buy |
20,992
+2,500
| +14% | +$1.1M | 0.09% | 219 |
|
|
2024
Q3 | $9.34M | Buy |
+18,492
| New | +$8.98M | 0.1% | 206 |
|
|
2024
Q1 | $9.12M | Sell |
16,892
-1,000
| -6% | -$546K | 0.1% | 218 |
|
|
2023
Q4 | $9.93M | Hold |
17,892
| – | – | 0.12% | 174 |
|
|
2023
Q3 | $7.82M | Sell |
17,892
-1,900
| -10% | -$947K | 0.1% | 211 |
|
|
2023
Q2 | $9.94M | Buy |
19,792
+2,900
| +17% | +$1.39M | 0.12% | 179 |
|
|
2023
Q1 | $8.45M | Sell |
16,892
-1,200
| -7% | -$574K | 0.11% | 202 |
|
|
2022
Q4 | $7.38M | Sell |
18,092
-5,356
| -23% | -$2.08M | 0.11% | 215 |
|
|
2022
Q3 | $8.22M | Hold |
23,448
| – | – | 0.1% | 200 |
|
|
2022
Q2 | $8.22M | Buy |
23,448
+3,100
| +15% | +$1.26M | 0.1% | 200 |
|
|
2022
Q1 | $11.1M | Sell |
20,348
-1,800
| -8% | -$947K | 0.11% | 191 |
|
|
2021
Q4 | $14.6M | Sell |
22,148
-426
| -2% | -$267K | 0.13% | 154 |
|
|
2021
Q3 | $14M | Sell |
22,574
-300
| -1% | -$202K | 0.13% | 148 |
|
|
2021
Q2 | $14.4M | Sell |
22,874
-400
| -2% | -$221K | 0.13% | 154 |
|
|
2021
Q1 | $11.4M | Sell |
23,274
-1,000
| -4% | -$501K | 0.1% | 194 |
|
|
2020
Q4 | $12.1M | Sell |
24,274
-2,700
| -10% | -$1.21M | 0.12% | 166 |
|
|
2020
Q3 | $10.6M | Hold |
26,974
| – | – | 0.12% | 164 |
|
|
2020
Q2 | $8.91M | Buy |
26,974
+2,382
| +10% | +$690K | 0.11% | 183 |
|
|
2020
Q1 | $5.96M | Sell |
24,592
-1,100
| -4% | -$287K | 0.1% | 205 |
|
|
2019
Q4 | $6.71M | Buy |
25,692
+500
| +2% | +$132K | 0.08% | 257 |
|
|
2019
Q3 | $6.85M | Buy |
25,192
+200
| +0.8% | +$55.7K | 0.09% | 249 |
|
|
2019
Q2 | $6.88M | Sell |
24,992
-1,700
| -6% | -$419K | 0.09% | 253 |
|
|
2019
Q1 | $5.97M | Buy |
26,692
+5,689
| +27% | +$1.17M | 0.07% | 270 |
|
|
2018
Q4 | $3.91M | Sell |
21,003
-2,700
| -11% | -$554K | 0.07% | 289 |
|
|
2018
Q3 | $5.92M | Sell |
23,703
-1,360
| -5% | -$330K | 0.09% | 244 |
|
|
2018
Q2 | $5.46M | Sell |
25,063
-33
| -0.1% | -$6.8K | 0.08% | 264 |
|
|
2018
Q1 | $4.8M | Sell |
25,096
-957
| -4% | -$177K | 0.07% | 292 |
|
|
2017
Q4 | $4.07M | Buy |
26,053
+4,509
| +21% | +$710K | 0.06% | 352 |
|
|
2017
Q3 | $3.35M | Buy |
21,544
+558
| +3% | +$88.2K | 0.06% | 340 |
|
|
2017
Q2 | $3.39M | Buy |
20,986
+2,152
| +11% | +$349K | 0.07% | 323 |
|
|
2017
Q1 | $2.91M | Sell |
18,834
-6,173
| -25% | -$851K | 0.07% | 317 |
|
|
2016
Q4 | $2.93M | Sell |
25,007
-1,596
| -6% | -$182K | 0.07% | 325 |
|
|
2016
Q3 | $3M | Sell |
26,603
-82
| -0.3% | -$8.64K | 0.07% | 339 |
|
|
2016
Q2 | $2.48M | Buy |
+26,685
| New | +$2.29M | 0.06% | 383 |
|
Other funds holding IDXX
Fjarde Ap-fonden's IDXX Position: Q2 2026 in Review
Fjarde Ap-fonden reduced its Idexx Laboratories (IDXX) stake by 7% in Q2 2026, selling an estimated $1.62M and leaving 38,532 shares worth $20.3M. The position accounts for 0.1% of the portfolio, ranked #195.
Fjarde Ap-fonden first reported a position in IDXX in Q2 2016 and has held it in 40 quarters since. The position peaked at $23.3M in Q1 2026. 1,303 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.
- Fjarde Ap-fonden held 38,532 shares of Idexx Laboratories worth $20.3M as of Q2 2026.
- Fjarde Ap-fonden sold 2,880 Idexx Laboratories shares in Q2 2026, an estimated $1.62M.
- Idexx Laboratories made up 0.1% of Fjarde Ap-fonden's portfolio in Q2 2026, its #195 holding.
- Fjarde Ap-fonden first reported a position in Idexx Laboratories in Q2 2016 and has held it in 40 quarters since.
- Fjarde Ap-fonden's Idexx Laboratories position peaked at $23.3M in Q1 2026.
- 1,303 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.
Based on Fjarde Ap-fonden's 13F filing for Q2 2026, filed 29 Jul 2026.